Biogen (BIIB) has risen sharply, recording gains of 20.61% in the past 4 weeks. However, the stock has corrected -0.64% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 19.38% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 6.58% and the 50-Day Moving Average is 17.85%. Biogen (NASDAQ:BIIB): On Fridays trading session , Opening price of the stock was $311.99 with an intraday high of $315.23. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $311.65. However, the stock managed to close at $313.94, a loss of 0.17% for the day. On the previous day, the stock had closed at $314.49. The total traded volume of the day was 993,791 shares.
The company Insiders own 0.32% of Biogen shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -8.87% . Institutional Investors own 85.81% of Biogen shares. During last six month period, the net percent change held by insiders has seen a change of -9.75%. Also, Major Brokerage house, Raymond James maintains its ratings on Biogen (NASDAQ:BIIB). In the latest research report, Raymond James raises the target price from $360 per share to $375 per share. According to the latest information available, the shares are now rated Strong Buy by the analysts at the agency. The rating by the firm was issued on August 2, 2016.
Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.